TY - JOUR
T1 - α2-adrenoceptor subsensitivity in mesenteric vascular bed of cholestatic rats
T2 - The role of nitric oxide and endogenous opioids
AU - Borhani, Amir Ali
AU - Houshmand, Golbahar
AU - Samini, Morteza
AU - Namiranian, Khodadad
AU - Hajrasouliha, Amir Reza
AU - Tavakoli, Sina
AU - Ebrahimi, Farzad
AU - Dehpour, Ahmad Raza
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2005/5/9
Y1 - 2005/5/9
N2 - Cholestasis is associated with vascular changes and in previous studies decreased response of visceral vessels of cholestatic animals to phenylephrine and acetylcholine has been shown. In the present study, the response of mesenteric vascular bed of cholestatic rats to clonidine (an α2-adrenoceptor agonist) was investigated and we also examined the role of endogenous opioids and nitric oxide (NO). Seven-day ligation of bile duct was used as the model to study cholestasis. Six groups of rats, each of which divided into two subgroups (bile duct-ligated and sham-operated), were examined. Three groups of animals were chronically treated with either normal saline, naltrexone (an opioid receptor antagonist, 20 mg/kg/day, s.c.) or aminoguanidine (a selective inducible nitric oxide synthase inhibitor, 150 mg/kg/day, s.c.) for 7 days. After 7 days the response of the mesenteric vascular bed to subsequent doses of clonidine was studied. In other two groups, 7 days after the operation, the response of the mesenteric vascular bed to clonidine in the presence of either yuhimbine, an α2- adrenoceptor antagonist, or N(ω)-nitro-l-arginine methyl ester (l-NAME), a non-selective nitric oxide synthase inhibitor, was studied. In the last group, vasodilation response to sodium nitroprusside (an endothelium-independent vasorelaxant) was evaluated. Clonidine caused vasodilation in a dose-dependent manner by acting on endothelial α2-adrenoceptors since its effect was antagonized by yohimbine, and this vasodilation was through the l-arginine pathway since there was no response in the presence of l-NAME in the perfusate. Compared to sham-operated rats, there was a significant right shift in the clonidine concentration curves of cholestatic animals. Maximum response in cholestatic rats was significantly lower comparing to the sham group (P < 0.01) and the dose of clonidine that causes 50% of maximum response (ED 50) was significantly higher in cholestatic rats (P < 0.05). Vasodilation response to sodium nitroprusside was the same in cholestatic and sham-operated rats. Seven-day treatment with aminoguanidine recovered the effect of cholestasis. Seven-day treatment with naltrexone caused an increase in maximum response (P < 0.01) and a decrease in ED50 (P < 0.05) in cholestatic rats, while this treatment in sham-operated rats caused a decrease in the maximum response (P < 0.01) and an increase in ED 50 (P < 0.05). This study showed that cholestasis is associated with decreased responsiveness of mesenteric vascular bed to clonidine and the cholestasis-associated NO overproduction and increased level of endogenous opioids may contribute to this process.
AB - Cholestasis is associated with vascular changes and in previous studies decreased response of visceral vessels of cholestatic animals to phenylephrine and acetylcholine has been shown. In the present study, the response of mesenteric vascular bed of cholestatic rats to clonidine (an α2-adrenoceptor agonist) was investigated and we also examined the role of endogenous opioids and nitric oxide (NO). Seven-day ligation of bile duct was used as the model to study cholestasis. Six groups of rats, each of which divided into two subgroups (bile duct-ligated and sham-operated), were examined. Three groups of animals were chronically treated with either normal saline, naltrexone (an opioid receptor antagonist, 20 mg/kg/day, s.c.) or aminoguanidine (a selective inducible nitric oxide synthase inhibitor, 150 mg/kg/day, s.c.) for 7 days. After 7 days the response of the mesenteric vascular bed to subsequent doses of clonidine was studied. In other two groups, 7 days after the operation, the response of the mesenteric vascular bed to clonidine in the presence of either yuhimbine, an α2- adrenoceptor antagonist, or N(ω)-nitro-l-arginine methyl ester (l-NAME), a non-selective nitric oxide synthase inhibitor, was studied. In the last group, vasodilation response to sodium nitroprusside (an endothelium-independent vasorelaxant) was evaluated. Clonidine caused vasodilation in a dose-dependent manner by acting on endothelial α2-adrenoceptors since its effect was antagonized by yohimbine, and this vasodilation was through the l-arginine pathway since there was no response in the presence of l-NAME in the perfusate. Compared to sham-operated rats, there was a significant right shift in the clonidine concentration curves of cholestatic animals. Maximum response in cholestatic rats was significantly lower comparing to the sham group (P < 0.01) and the dose of clonidine that causes 50% of maximum response (ED 50) was significantly higher in cholestatic rats (P < 0.05). Vasodilation response to sodium nitroprusside was the same in cholestatic and sham-operated rats. Seven-day treatment with aminoguanidine recovered the effect of cholestasis. Seven-day treatment with naltrexone caused an increase in maximum response (P < 0.01) and a decrease in ED50 (P < 0.05) in cholestatic rats, while this treatment in sham-operated rats caused a decrease in the maximum response (P < 0.01) and an increase in ED 50 (P < 0.05). This study showed that cholestasis is associated with decreased responsiveness of mesenteric vascular bed to clonidine and the cholestasis-associated NO overproduction and increased level of endogenous opioids may contribute to this process.
KW - Cholestasis
KW - Clonidine
KW - Mesenteric vascular bed
KW - Nitric oxide
KW - Opioid
KW - α-Adrenoceptor
UR - http://www.scopus.com/inward/record.url?scp=19344373417&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=19344373417&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2005.03.015
DO - 10.1016/j.ejphar.2005.03.015
M3 - Article
C2 - 15910805
AN - SCOPUS:19344373417
SN - 0014-2999
VL - 514
SP - 183
EP - 189
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 2-3
ER -